Dapagliflozin and Anemia in Patients with Chronic Kidney Disease

Akihiko Koshino; Meir Schechter; Glenn M Chertow; Priya Vart; Niels Jongs; Robert D Toto; Peter Rossing; Ricardo Correa-Rotter; John J V McMurray; Jose Luis Górriz; Rey Isidto; Naoki Kashihara; Anna Maria Langkilde; David C Wheeler; Hiddo J L Heerspink

doi:10.1056/EVIDoa2300049

Dapagliflozin and Anemia in Patients with Chronic Kidney Disease

NEJM Evid. 2023 Jun;2(6):EVIDoa2300049. doi: 10.1056/EVIDoa2300049. Epub 2023 May 19.

Authors

Akihiko Koshino^{1

2}, Meir Schechter^{1

3

4}, Glenn M Chertow⁵, Priya Vart¹, Niels Jongs¹, Robert D Toto⁶, Peter Rossing^{7

8}, Ricardo Correa-Rotter⁹, John J V McMurray¹⁰, Jose Luis Górriz¹¹, Rey Isidto¹², Naoki Kashihara¹³, Anna Maria Langkilde¹⁴, David C Wheeler¹⁵, Hiddo J L Heerspink^{1

16}

Affiliations

¹ Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
² Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.
³ Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem.
⁴ Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem.
⁵ Departments of Medicine and Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California.
⁶ Department of Internal Medicine, UT Southwestern Medical Center, Dallas.
⁷ Steno Diabetes Center Copenhagen, Herlev, Denmark.
⁸ Department of Clinical Medicine, University of Copenhagen, Copenhagen.
⁹ The National Medical Science and Nutrition Institute Salvador Zubiran, Mexico City.
¹⁰ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kindom.
¹¹ Hospital Clinico Universitario de Valencia, University of Valencia, Valencia, Spain.
¹² College of Medicine, West Visayas State University, Iloilo City, Philippines.
¹³ Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan.
¹⁴ BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
¹⁵ Department of Renal Medicine, University College London, London.
¹⁶ The George Institute for Global Health, UNSW Sydney, Sydney.

PMID: 38320128
DOI: 10.1056/EVIDoa2300049

Abstract

DAPA and Anemia in Patients with CKDThis post hoc analysis of the DAPA-CKD (Dapagliflozin in Patients with Chronic Kidney Disease) trial assessed the impact of dapagliflozin treatment on the correction and prevention of anemia. Results over a 2.4-year median follow-up show that dapagliflozin is associated with increase in hematocrit, correction of anemia, and reduced risk of incident anemia in patients with CKD with or without type 2 diabetes.

Publication types

Clinical Trial

MeSH terms

Anemia*
Benzhydryl Compounds
Diabetes Mellitus, Type 2*
Glucosides*
Humans
Renal Insufficiency, Chronic*

Substances

Benzhydryl Compounds
dapagliflozin
Glucosides